Atara Biotherapeutics, Inc.
ATRA$39M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaTHOUSAND OAKS38 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
ATRA News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
EBV-induced Lymphomas
EBV-specific T cells (EBV-CTLs)
EBV-induced Lymphomas
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas | - | - |
EBV-specific T cells (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply